395 related articles for article (PubMed ID: 15598972)
1. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
[TBL] [Abstract][Full Text] [Related]
2. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
[TBL] [Abstract][Full Text] [Related]
3. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD; Yu W; Zou A; Jegla T; Wagoner PK
Mol Pharmacol; 2000 Sep; 58(3):591-600. PubMed ID: 10953053
[TBL] [Abstract][Full Text] [Related]
4. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
Tatulian L; Delmas P; Abogadie FC; Brown DA
J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
[TBL] [Abstract][Full Text] [Related]
5. Activation of KCNQ2/3 potassium channels by novel pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives.
Jia C; Qi J; Zhang F; Mi Y; Zhang X; Chen X; Liu L; Du X; Zhang H
Pharmacology; 2011; 87(5-6):297-310. PubMed ID: 21577044
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying modulation of neuronal KCNQ2/KCNQ3 potassium channels by extracellular protons.
Prole DL; Lima PA; Marrion NV
J Gen Physiol; 2003 Dec; 122(6):775-93. PubMed ID: 14638935
[TBL] [Abstract][Full Text] [Related]
7. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
[TBL] [Abstract][Full Text] [Related]
8. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
9. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
Wickenden AD; Zou A; Wagoner PK; Jegla T
Br J Pharmacol; 2001 Jan; 132(2):381-4. PubMed ID: 11159685
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
11. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
Tatulian L; Brown DA
J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
[TBL] [Abstract][Full Text] [Related]
12. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
Rundfeldt C; Netzer R
Neurosci Lett; 2000 Mar; 282(1-2):73-6. PubMed ID: 10713399
[TBL] [Abstract][Full Text] [Related]
13. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
[TBL] [Abstract][Full Text] [Related]
14. Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
Punke MA; Friederich P
Anesthesiology; 2004 Aug; 101(2):430-8. PubMed ID: 15277926
[TBL] [Abstract][Full Text] [Related]
15. Antihistamine mepyramine directly inhibits KCNQ/M channel and depolarizes rat superior cervical ganglion neurons.
Liu B; Zhang X; Wang C; Zhang G; Zhang H
Neuropharmacology; 2008 Mar; 54(4):629-39. PubMed ID: 18222495
[TBL] [Abstract][Full Text] [Related]
16. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.
Martire M; Castaldo P; D'Amico M; Preziosi P; Annunziato L; Taglialatela M
J Neurosci; 2004 Jan; 24(3):592-7. PubMed ID: 14736843
[TBL] [Abstract][Full Text] [Related]
17. Pre- and postsynaptic activation of M-channels by a novel opener dampens neuronal firing and transmitter release.
Peretz A; Sheinin A; Yue C; Degani-Katzav N; Gibor G; Nachman R; Gopin A; Tam E; Shabat D; Yaari Y; Attali B
J Neurophysiol; 2007 Jan; 97(1):283-95. PubMed ID: 17050829
[TBL] [Abstract][Full Text] [Related]
18. Sequence determinants of subtype-specific actions of KCNQ channel openers.
Wang AW; Yang R; Kurata HT
J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
[TBL] [Abstract][Full Text] [Related]
19. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy.
Cooper EC; Aldape KD; Abosch A; Barbaro NM; Berger MS; Peacock WS; Jan YN; Jan LY
Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4914-9. PubMed ID: 10781098
[TBL] [Abstract][Full Text] [Related]
20. Expression of a calmodulin-binding KCNQ2 potassium channel fragment modulates neuronal M-current and membrane excitability.
Shahidullah M; Santarelli LC; Wen H; Levitan IB
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16454-9. PubMed ID: 16263935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
